Form 4: Terns Pharmaceuticals Director Radhika Tripuraneni Acquires Stock Options in Lieu of Cash Retainer

Radhika Tripuraneni, a director at Terns Pharmaceuticals, acquired stock options in lieu of cash retainer fees, according to a recent SEC Form 4 filing.

Summary

• Radhika Tripuraneni, a director at Terns Pharmaceuticals, acquired 4,676 stock options on July 1, 2024.
• The options were granted in lieu of a $20,000 cash retainer fee for the third and fourth quarters of 2024, as per the Issuer's Non-Employee Director Compensation Policy.
• The exercise price of the options is $6.85.
• The options vest monthly, with full vesting by January 1, 2025, and expire on June 30, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The director is taking stock options in lieu of cash, which could be seen as a positive sign of confidence in the company's future.

Positives

• The director's decision to take stock options instead of cash may signal confidence in the company's future performance.

Industry Context

Director compensation packages often include stock options to align the interests of directors with those of shareholders. This is a common practice in the pharmaceutical industry to incentivize long-term growth and value creation.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a common practice in the pharmaceutical industry.
• Comparable companies such as Madrigal Pharmaceuticals and Viking Therapeutics also utilize stock options as part of their director compensation packages.
• The vesting schedule and exercise price are typical for such grants, aligning with industry benchmarks for incentivizing long-term performance.

Stakeholder Impact

• Shareholders may view the director's acceptance of stock options positively, as it aligns their interests with the company's long-term success.

Key Dates